US2016256386A1PendingUtilityA1

Methods and compositions for localized agent delivery

63
Assignee: MASSACHUSETTS INST TECHNOLOGYPriority: Nov 24, 2008Filed: Feb 4, 2016Published: Sep 8, 2016
Est. expiryNov 24, 2028(~2.3 yrs left)· nominal 20-yr term from priority
Inventors:Darrell J. IrvineMatthias StephanJaehyun MoonAnna Bershteyn
A61K 47/6937A61K 47/6911A61K 45/06C12N 2310/14C12N 5/0647C12N 15/87A61K 31/711A61K 9/19A61P 31/00A61K 9/5153A61K 35/28A61K 9/127A61K 39/395A61K 38/2086C12N 15/113A61K 47/46A61K 47/6901A61K 38/19A61K 9/5146A61K 39/39A61K 2035/124C12N 5/0006A61P 35/00A61K 38/20A61K 31/7105B82Y 5/00A61K 9/146C07K 16/00A61P 37/06A61K 40/4273A61K 40/32A61K 40/11A61K 2239/38A61K 2239/57C12N 5/0636A61K 38/00
63
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The invention provides compositions and methods for delivering agents to localized regions, tissues, or organs in vivo by conjugating agent-loaded nanoparticles to cells having homing capability. The agents may be therapeutic or diagnostic agents such as cancer chemotherapeutic agents and imaging agents respectively.

Claims

exact text as granted — not AI-modified
1 . A biodegradable nanoparticle comprising maleimide groups on its exterior surface. 
     
     
         2 . The nanoparticle of  claim 1 , wherein the nanoparticle further comprises a lipid bilayer surface. 
     
     
         3 . The nanoparticle of  claim 1 , wherein the nanoparticle comprises a poly(lactide-co-glycolide) (PLGA) core. 
     
     
         4 . The nanoparticle of  claim 1 , wherein the nanoparticle further comprises an agent. 
     
     
         5 . The nanoparticle of  claim 1 , wherein the nanoparticle further comprises a plurality of agents. 
     
     
         6 . The nanoparticle of  claim 4 , wherein the agent is an antibody. 
     
     
         7 . The nanoparticle of  claim 4 , wherein the agent is an antigen. 
     
     
         8 . The nanoparticle of  claim 4 , wherein the agent is an adjuvant. 
     
     
         9 . The nanoparticle of  claim 8 , wherein the adjuvant is a TLR ligand. 
     
     
         10 . The nanoparticle of  claim 4 , wherein the agent is a nucleic acid. 
     
     
         11 . The nanoparticle of  claim 10 , wherein the nucleic acid is an siRNA. 
     
     
         12 . The nanoparticle of  claim 4 , wherein the agent is an anti-cancer agent. 
     
     
         13 . The nanoparticle of  claim 4 , wherein the agent is a cytokine. 
     
     
         14 . The nanoparticle of  claim 4 , wherein the agent is an interleukin. 
     
     
         15 . The nanoparticle of  claim 5 , wherein the plurality of agents comprises an antigen and an adjuvant. 
     
     
         16 . The nanoparticle of  claim 5 , wherein the plurality of agents comprises an adjuvant and an anti-cancer agent. 
     
     
         17 . The nanoparticle of  claim 1 , wherein the nanoparticle is 50-500 nanometers in diameter. 
     
     
         18 . The nanoparticle of  claim 1 , wherein the nanoparticle is about 150 nanometers in diameter. 
     
     
         19 . The nanoparticle of  claim 1 , in a lyophilized form.

Join the waitlist — get patent alerts

Track US2016256386A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.